Financial Review: Biocorrx (OTCMKTS:BICX) vs. Embecta (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) and Biocorrx (OTCMKTS:BICX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Embecta and Biocorrx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3	2	0	0	1.40
Biocorrx	0	1	0	0	2.00

Embecta currently has a consensus target price of $11.00, suggesting a potential upside of 228.36%. Given Embecta’s higher probable upside, research analysts clearly believe Embecta is more favorable than Biocorrx.

Valuation & Earnings

This table compares Embecta and Biocorrx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08 billion	0.18	$95.40 million	$1.90	1.76
Biocorrx	$800,000.00	12.54	-$3.44 million	($0.16)	-2.12

Embecta has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 21.4% of Biocorrx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Embecta and Biocorrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Biocorrx	N/A	N/A	-73.40%

Volatility & Risk

Embecta has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.

Summary

Embecta beats Biocorrx on 9 of the 13 factors compared between the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.